Development of Mouse Ascites Tumor Sublines Resistant to Triethylene Melamine
1961

Development of Mouse Tumors Resistant to Triethylene Melamine

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): ANNA MARIA WILLIAMS, ELAINE JORANGER

Primary Institution: University of Wisconsin Medical School

Hypothesis

Can mouse ascites tumors be developed to resist alkylating agents like triethylene melamine?

Conclusion

Mouse ascites tumors resistant to triethylene melamine were successfully developed and showed increased sensitivity to certain other drugs.

Supporting Evidence

  • Sublines of Ehrlich carcinoma and Sarcoma 180 were developed to resist triethylene melamine.
  • The resistant subline showed increased sensitivity to several antimetabolites.
  • The resistance was stable for at least 8 transplant generations without the drug.

Takeaway

Scientists made mouse tumors that can survive a medicine called triethylene melamine, and these tumors can be treated better with other medicines.

Methodology

The study involved developing resistant sublines of mouse ascites tumors through consecutive passages in mice treated with triethylene melamine.

Limitations

The study does not address the mechanisms of resistance development, such as selection or mutation.

Participant Demographics

Female white Swiss mice, 20-25 g.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication